31st Aug 2020 16:18
GlaxoSmithKline PLC - Brentford, west London-based pharmaceutical firm - Glaxo and partner Vir Biotechnology Inc say on Monday the first patient was dosed last week in the Phase 2/3 study of their anti-SARS-CoV-2 monoclonal antibody for the early treatment of COVID-19 in patients who are at high risk of hospitalisation. Initial study results may be available before the end of 2020, they say, with early access to the treatment possible as soon as the first half of 2021. The COMET-ICE study will enrol about 1,300 patients with early symptomatic infection worldwide. The name of the study refers to COVID-19 monoclonal antibody efficacy trial - intent to care early. "Treating those with early COVID-19 disease so that it doesn't become worse is critical both for the patients and for society," says Vir Chief Executive Officer George Scangos. "Hospital systems are overwhelmed worldwide, with new infections continuing to strain already limited resources."
By Tom Waite; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline